Phase 1 Kidney TrialThe wording of the press release on the New Zealand Phase 1 kidney trial may be a signal of apabetalone may be a signal that Mr Paradis is beginning to do his job. The announcement is clear and direct in terms of the positive impact of 1 dose of apabetalone on significantly reducing key proteins involved in kidney disease. It is done in a way that the public can understand.
The part is missing the the answer to the question "what is the potential health impact on people with this (ese) severe health problems?" e.g. better life, prolonged life, curing the disease,...?
https://www.resverlogix.com/media/news-releases.html?article=134227#.WIitZ7YrK7o January 23, 2017
Several Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone CALGARY, Jan. 23, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced preliminary results from the New Zealand based Phase 1 trial with severe kidney (renal) impaired patients.
The data showed remarkable results in reducing inflamed protein biomarkers in patients with severe kidney impairment versus healthy control patients. It is believed that
this is the first time in medical history that a direct connection of this type can be made between epigenetic regulation and its potential for positive disease impact. Both the healthy group and the severely impaired kidney group received equal amounts of apabetalone.
"It was shocking and highly encouraging to see the direct comparison of the protein data ranked by magnitude of effect in the two groups.
For the first time, epigenetic and BET inhibition clinical data has been shown to differentially affect genes and proteins between advanced chronic kidney disease (CKD) patients and normal subjects," stated Donald McCaffrey, President and CEO.
Etc.
Pretty good news.
On a separate question, what is happenning with Stockhouse....unstable again?
Cheers
Toinv